With the US Election, there has been a renewed interest in psychedelic stocks, driven by RFK Jr.’s recent comments on psychedelic research and his strong critique of the pharmaceutical industry, labeling America as one of the sickest countries in the world. This renewed focus has placed a spotlight on the psychedelic industry, which is conducting critical mental health trials to address conditions such as depression, anxiety, and PTSD.

The episode will cover 24 companies with over a $2 million market cap, including 18 micro-cap and 6 small-cap stocks. Of these, we’ll identify which companies are leading in 1-year returns and which are lagging.